Jose Fernando Moura, PhD· @FernandoOnco · X·· 2 天前评分70
正文 · 原文
The RASolute 302 brought the standing ovation. 👏
Now the SCLC community is hoping DeLLphi-305 will bring the same emotion to #ESMO26.
Different tumors. Same hope. More time for our patients. 🤞
#DeLLphi305 #SCLC #LCSM @Amgen @BalazsHalmosMD @StephenVLiu @myESMO
146 浏览 · 2 赞 · 0 转发 · 0 回复
会议摘要
LBA3按 Presidential Symposium I 对上
Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.org来源：Jose Fernando Moura, PhD · x.com